News Search Results
Nov 04, 2025, 12:58 ET Healthcare Analytics Market Size to grow USD 532.75 Billion by 2035, at 25.75% CAGR | Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Nov 04, 2025, 12:55 ET INTREPID Alliance Launches Antiviral Toolbox to Support Global Research Community
journey. "The INTREPID Alliance Antiviral Toolbox comes at a critical time, especially for small biotechnology companies that have limited resources to advance their promising antiviral research," said John C. Pottage, Jr., M.D., Lead Scientific Consultant
More news about: INTREPID Alliance
Nov 04, 2025, 11:00 ET Amyris Launches New Brand and Website to align with Strategic Growth Pillars.
how Amyris is uniquely positioned to help its partners 'Unlock The Chemistry of Life'™," Fortmann said. "With our powerful capabilities in biotechnology, scale-up, and biomanufacturing, we are prepared to help our partners access the high-performing chemistry found throughout living systems, enabling
More news about: Amyris, Inc.
Nov 04, 2025, 10:50 ET Point-of-Care Molecular Diagnostics Market Surges to USD 15.2 Billion by 2033, Propelled by 10.2% CAGR - Verified Market Reports®
System Market Size By Deployment Type (On-Premise, Cloud-Based), By Component (Software, Services), By End-User (Pharmaceutical Companies, Biotechnology Companies), By Phase (Phase I, Phase II), By Functionality (Study Management, Site Management), By Geographic Scope And Forecast
More news about: Verified Market Reports
Nov 04, 2025, 10:00 ET Thomas Cahill Joins Keebeck Wealth Management's Advisory Board
research at Duke University and Stanford University, under the mentorship of three Nobel Laureates, provided the foundation for his transition into biotechnology investments, beginning with his work on the biophysical properties of cellular receptors. "Bruce has built something truly
More news about: Keebeck Wealth Management
Nov 04, 2025, 09:04 ET Introducing LOAM: Redefining Gut Health with the Launch of Its First Clinically Grounded Prebiotic Fiber Formula
LOS ANGELES, Nov. 4, 2025 /PRNewswire/ -- Today, LOAM, a biotechnology company building the next generation of microbiome support, introduces a revolutionary advancement in gut health with the launch of their first
More news about: LOAM
Nov 04, 2025, 09:02 ET Phenomix Sciences Expands Evidence for MyPhenome™ Test Predicting GLP-1 Response and Obesity Risk in Large, Diverse Populations
Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, today announced results from new research presented at Obesity Week 2025 demonstrating the continued clinical utility of its MyPhenome™
More news about: Phenomix Sciences
Nov 04, 2025, 09:00 ET Breakthrough Properties Completes One Helix, A Cutting-edge Research Facility Fully Leased to AstraZeneca
around the world and support scientific innovation across biotechnology, agriculture, and nutrition. Breakthrough combines Tishman Speyer's decades of global real estate development experience with Bellco Capital's industry-making biotechnology entrepreneurship to reimagine environments where companies
More news about: Breakthrough Properties
Nov 04, 2025, 09:00 ET Breakthrough Properties Completes One Helix, A Cutting-edge Research Facility Fully Leased to AstraZeneca
around the world and support scientific innovation across biotechnology, agriculture, and nutrition. Breakthrough combines Tishman Speyer's decades of global real estate development experience with Bellco Capital's industry-making biotechnology entrepreneurship to reimagine environments where companies
More news about: Breakthrough Properties
Nov 04, 2025, 08:32 ET iLeukon Receives FDA Clearance of IND Application for A Phase II Study of mRNA-based non-alpha IL-2 variant, ILKN421H, in Advanced Non-Small Cell Lung Cancer (NSCLC)
SAN DIEGO, Nov. 4, 2025 /PRNewswire/ -- iLeukon Therapeutics, Inc., a San Diego-based clinical-stage biotechnology company developing next-generation mRNA-based immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared its
More news about: iLeukon Therapeutics
Nov 04, 2025, 08:30 ET Ensuring compliance with animal-free raw materials in CGT, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 04, 2025, 08:30 ET Using Imaging in Clinical Trials to Improve Data and Decisions, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Nov 04, 2025, 07:05 ET AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform
this foundation, AmacaThera leverages its proprietary hydrogel platform to co-develop innovative drug delivery solutions with pharmaceutical and biotechnology partners. The platform's inherent versatility enables the creation of long-acting formulations that enhance therapeutic efficacy, improve patient
More news about: AmacaThera
Nov 04, 2025, 07:00 ET Magnet Biomedicine Appoints Bharat Reddy, Ph.D., as Chief Business Officer
historically difficult-to-drug proteins. About Magnet BiomedicineMagnet Biomedicine is a biotechnology company advancing molecular glue discovery with rational selection and design. Magnet is harnessing the vast untapped potential of TrueGlues to
More news about: Magnet Biomedicine
Nov 04, 2025, 07:00 ET NewcelX CEO Issues Letter to Shareholders
The merger between NLS Pharmaceutics Ltd. ("NLS") and Kadimastem Ltd. ("Kadimastem") established NewcelX Ltd., a biotechnology company that combines Kadimastem's advanced cell-therapy platforms with NLS's neuroscience and small-molecule expertise to develop treatments for
More news about: NewcelX Ltd.
Nov 03, 2025, 19:00 ET Kaigene Enters into Exclusive Licensing Agreement with Celltrion for Novel Antibody Therapeutics in Autoimmune Diseases
ROCKVILLE, Md., Nov. 3, 2025 /PRNewswire/ -- Kaigene Inc., a U.S.-based biotechnology company pioneering next-generation antibody therapeutics for autoimmune disorders, announced today that it has entered into an exclusive global
More news about: Kaigene
Nov 03, 2025, 16:05 ET AAVivo, Inc. to Present at Society for Immunotherapy of Cancer 2025
AAVivo, Inc., a pioneering biotechnology company developing novel, precision targeted biotherapeutics to enable in vivo generation of CAR-T cells, today announced a presentation
More news about: AAVivo, Inc.
Nov 03, 2025, 16:01 ET HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Nov 03, 2025, 11:03 ET BrainXell Therapeutics Unveils Promising Preclinical Data Demonstrating Efficacy of BXT-110, an Autologous iPSC-Derived Neuronal Therapy, in Parkinson's Disease
BrainXell Therapeutics BrainXell Therapeutics, a division of BrainXell, Inc., is a San Diego–based biotechnology company pioneering regenerative cell therapies for neurodegenerative diseases. Founded on the research of Dr. Su-Chun Zhang, MD, PhD, Advising CSO,
More news about: BrainXell, Inc.
Nov 03, 2025, 10:33 ET Lakewood-Amedex Biotherapeutics to Participate in Panel Discussion at BioFlorida's "Florida Innovation Conference"
made by innovative Florida-based biotechnology companies," said Kelvin Cooper, Ph.D., Chief Executive Officer and Senior Vice President of Research and Development at Lakewood-Amedex Biotherapeutics. "Many of today's leading medications began as discoveries by biotechnology entrepreneurs seeking to address
More news about: Lakewood-Amedex Biotherapeutics Inc.
Nov 03, 2025, 09:18 ET Thryv Therapeutics to Participate in Upcoming 2025 Healthcare Investor Conferences
MONTREAL, Nov. 3, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic
More news about: Thryv Therapeutics Inc.
Nov 03, 2025, 09:15 ET NeuroSense to Host Investor Webinar on December 8, 2025
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that it will host an investor update meeting on December
More news about: NeuroSense
Nov 03, 2025, 09:05 ET Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition
Calif., Nov. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R2891, a potent and
More news about: Rigel Pharmaceuticals, Inc.
Nov 03, 2025, 09:01 ET Orna Therapeutics Announces Multiple Presentations Supporting its in vivo CAR Programs for Autoimmune Diseases at the 67th American Society of Hematology Annual Meeting
WATERTOWN, Mass., Nov. 3, 2025 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to engineering immune cells in vivo to treat autoimmune and oncology diseases, today announced upcoming presentations at
More news about: Orna Therapeutics
Nov 03, 2025, 08:30 ET Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
development of differentiated targeted radiotherapies, announced today that Sandesh Seth, Chairman and CEO will be participating in the Stephens Biotechnology Virtual Fireside Chat. During the conference, members of Actinium's management team will also be available for one-on-one meetings with investors.
More news about: Actinium Pharmaceuticals, Inc.